Protein Tyrosine Phosphatase (PTP) PTPRR
- Known as:
- Protein Tyrosine Phosphatase (PTP) PTPRR
- Catalog number:
- E-3311
- Product Quantity:
- 20 ug
- Category:
- -
- Supplier:
- Bioner
- Gene target:
- Protein Tyrosine Phosphatase (PTP) PTPRR
Related genes to: Protein Tyrosine Phosphatase (PTP) PTPRR
- Gene:
- ACP1 NIH gene
- Name:
- acid phosphatase 1
- Previous symbol:
- -
- Synonyms:
- HAAP, LMW-PTP, LMWPTP
- Chromosome:
- 2p25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-09-15
- Gene:
- DUSP1 NIH gene
- Name:
- dual specificity phosphatase 1
- Previous symbol:
- PTPN10
- Synonyms:
- HVH1, CL100, MKP-1
- Chromosome:
- 5q35.1
- Locus Type:
- gene with protein product
- Date approved:
- 1993-03-03
- Date modifiied:
- 2015-09-11
- Gene:
- HACD1 NIH gene
- Name:
- 3-hydroxyacyl-CoA dehydratase 1
- Previous symbol:
- PTPLA
- Synonyms:
- CAP
- Chromosome:
- 10p12.33
- Locus Type:
- gene with protein product
- Date approved:
- 1999-01-22
- Date modifiied:
- 2016-01-15
- Gene:
- HACD2 NIH gene
- Name:
- 3-hydroxyacyl-CoA dehydratase 2
- Previous symbol:
- PTPLB
- Synonyms:
- -
- Chromosome:
- 3q21.1
- Locus Type:
- gene with protein product
- Date approved:
- 1999-01-22
- Date modifiied:
- 2016-01-15
- Gene:
- HACD3 NIH gene
- Name:
- 3-hydroxyacyl-CoA dehydratase 3
- Previous symbol:
- PTPLAD1
- Synonyms:
- B-ind1, HSPC121
- Chromosome:
- 15q22.31
- Locus Type:
- gene with protein product
- Date approved:
- 2005-11-11
- Date modifiied:
- 2016-01-15
Related products to: Protein Tyrosine Phosphatase (PTP) PTPRR
Related articles to: Protein Tyrosine Phosphatase (PTP) PTPRR
- Air pollution has been increasingly associated with epilepsy risk, but the underlying biological mechanisms remain unclear. - Source: PubMed
Publication date: 2026/08/19
He ZihuaYin JianqiongYang QuanLiu ShengyiWang JiaqiZhou XiaoyuYi TongZhou DongLi Jinmei - ObjectiveTo investigate whether naringin enhances the chemosensitivity of nasopharyngeal carcinoma-derived CNE2 cells to paclitaxel and identify potential molecular mediators.MethodsCNE2 cells were treated with naringin alone or in combination with paclitaxel, cisplatin, or 5-fluorouracil. Cell viability, proliferation, and migration were assessed using cell counting kit-8 and Transwell assays. Transcriptomic profiling followed by bioinformatic analysis of Gene Expression Omnibus datasets (GSE53819, GSE12452, and GSE102349) was performed to identify nasopharyngeal carcinoma prognosis-related genes. overexpression was established via lentiviral transduction, and pharmacological inhibition was performed using ASP9521. mRNA and protein expression were validated using reverse transcription quantitative polymerase chain reaction and Western blot analysis.ResultsNaringin (160 μM) demonstrated a trend toward reducing the half-maximal inhibitory concentration of paclitaxel from 10.52 to 8.04 nM; however, it did not significantly alter sensitivity to cisplatin or 5-fluorouracil. Combined treatment with 2 nM paclitaxel and 160 μM naringin synergistically suppressed CNE2 proliferation and migration compared with that using either agent alone ( < 0.05). Bioinformatic analysis revealed that high expression was correlated with improved survival in patients with nasopharyngeal carcinoma ( < 0.05), whereas high , , , and expressions were correlated with poorer outcomes. Reverse transcription quantitative polymerase chain reaction confirmed that both naringin and paclitaxel upregulated mRNA, with the combination producing the strongest effect. Gain-of-function studies demonstrated that overexpression significantly enhanced paclitaxel sensitivity, with half-maximal inhibitory concentration values decreasing from 13.63 to 6.994 nM in CNE2 cells and from 8.534 to 4.668 nM in CNE1 cells. Furthermore, the specific inhibitor, ASP9521, significantly attenuated the synergistic anti-proliferative and anti-migratory effects of paclitaxel + naringin in CNE2 cells, confirming that naringin enhances chemosensitivity to paclitaxel by upregulating AKR1C3 expression.ConclusionsNaringin sensitizes CNE2 cells to paclitaxel, potentially via upregulation. This flavonoid may represent a low-toxicity adjunct to enhance the efficacy of paclitaxel in nasopharyngeal carcinoma. - Source: PubMed
Publication date: 2026/07/29
Huang ZhenheQiu YumeiLiu FangchuChen XiaoliWang Xintao - Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant digestive tumor with an extremely low 5-year survival rate, and KRAS mutation is its predominant molecular characteristic. Protein tyrosine phosphatase receptor R (PTPRR) functions as a tumor suppressor in most cancers; however, its expression pattern, biological function, and regulatory mechanism in PDAC remain largely unknown. - Source: PubMed
Publication date: 2026/05/13
Li RunyangXu XuechunZhang WenqingZhan Yan-Yan - Cirrhosis and sarcopenia frequently coexist and are associated with poor clinical outcomes; however, their shared genetic basis remains incompletely understood. - Source: PubMed
Publication date: 2026/05/11
Ran ShuLi HaopengLi ZhichenLi YuehuaFang YapengLiu Baolin - The CONSTANS, CONSTANS-like, and TIMING OF CAB EXPRESSION 1 (CCT) domain proteins are key regulators of flowering time and circadian rhythms in annual plants, but their diversity and temporal expression patterns in perennial trees remain poorly understood. - Source: PubMed
Publication date: 2026/03/20
Zang RuiLi YueDai Xiaokang